Serpin Pharma

Executive Summary

Serpin Pharma is a privately held biotechnology company based in Charlottesville, Virginia, developing a novel class of anti-inflammatory therapeutics derived from natural SERPIN proteins. Its lead candidate, SP16, is a peptide that selectively targets a key pathway involved in harmful inflammation, aiming to restore immune balance in diseases with high unmet medical need. The company's platform leverages the body's own regulatory mechanisms to address conditions such as acute respiratory distress syndrome (ARDS), sepsis, and other inflammatory disorders. Founded in 2015, Serpin Pharma has advanced SP16 through preclinical studies and early-phase clinical trials, demonstrating promising safety and efficacy signals. The company is currently seeking additional funding and partnerships to support further clinical development and regulatory milestones. With a focus on modulating the inflammatory response without causing immunosuppression, SP16 has the potential to become a first-in-class therapy for acute and chronic inflammatory conditions. Serpin Pharma's approach targets a validated mechanism, which may reduce development risk and accelerate the path to approval.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 2 Trial for SP16 in ARDS40% success
• Q2 2026Publication of Phase 1 Safety and Biomarker Data70% success
• Q3 2026Strategic Partnership or Non-Dilutive Funding Announcement50% success